Complement C5a potentiates uric acid crystal-induced IL-1β production.

Area of Science:

• Immunology
• Complement system
• Inflammasome biology

Background:

• Gout pathogenesis involves uric acid crystals activating inflammasomes and releasing IL-1β.
• The role of complement activation, specifically C5a, in MSU crystal-induced inflammasome activation is not well understood.

Purpose of the Study:

• To investigate the interaction between complement activation (C5a) and monosodium urate (MSU) crystal-induced inflammasome activation.
• To elucidate the role of C5a in regulating IL-1β production in response to MSU crystals.

Main Methods:

• Experiments conducted using human whole blood and primary monocytes.
• Analysis of cytokine/chemokine production, IL-1β release, and dependence on caspase-1, Ca(2+) mobilization, K(+) efflux, and cathepsin B activity.

Main Results:

• MSU crystal-induced cytokine/chemokine production in human blood is primarily regulated by C5a via its receptor.
• C5a induces pro-IL-1β and IL-1β production in monocytes and potentiates IL-1β release induced by MSU or cholesterol crystals.
• This potentiation is dependent on caspase-1, intracellular Ca(2+) mobilization, K(+) efflux, and cathepsin B activity.

Conclusions:

• C5a acts as an endogenous priming signal essential for initiating uric acid crystal-induced IL-1β production.
• C5a represents a potential therapeutic target, alongside IL-1β antagonists, for treating gout and other complement-dependent, inflammasome-associated diseases.